1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Enanta’s Phase II Challenge Data Position A Second Potential RSV Therapy

 
• By Joseph Haas

One of Enanta’s two antivirals in development for RSV showed efficacy in a healthy patient challenge trial. But analysts say field studies of infected patients are more telling.

RSV illus
Enanta is advancing two antivirals to treat RSV infections • Source: Shutterstock

Virology-focused Enanta Pharmaceuticals, Inc. took a positive step in its two-mechanism approach to providing a treatment for respiratory syncytial virus (RSV) on 26 September as its RSV L-protein inhibitor EDP-323 succeeded in a Phase IIa challenge study of healthy volunteers. But analysts called upcoming Phase IIb data for the firm’s N-protein inhibitor zelicapavir in pediatric RSV patients potentially the greater inflection point for Enanta’s program.

Key Takeaways

  • Enanta, with two antivirals in mid-stage development to treat RSV infection, reported positive Phase IIa challenge data for its novel RSV L-protein inhibitor.

On a same-day call, Enanta CEO Jay Luly asserted that the two Phase II candidates comprise “the leading portfolio of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.